Drugs / Slavinorm®
Slavinorm®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05933720 | Apr 2023 → Jun 2026 overdue | peripheral arterial occlusive disease 1 | Ryazan State Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Slavinorm | “The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients...” NCT05933720 ↗ |
| Known as | vascular polypeptides Slavinorm, a derivative from cattle vessels | “vascular polypeptides Slavinorm®, a derivative from cattle vessels” NCT05933720 ↗ |
| Modality | Protein / enzyme biologic | “The patients who undergo treatment with a complex of polypeptides isolated from the vessels of cattle is administered in / m, adults 1 vial (5 mg) 1 time / day 2 times a week.” NCT05933720 ↗ |
| Route | Intramuscular | “is administered in / m” NCT05933720 ↗ |